Chimeric antigen receptor therapy meets mRNA technology

  • Trends Biotechnol. 2024 Feb;42(2):228-240. doi: 10.1016/j.tibtech.2023.08.005.
Jiacai Wu  1 ,  Weigang Wu  2 ,  Boping Zhou  3 ,  Bin Li  4
Affiliations
  • 1. Department of Infectious Disease, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology and The Second Clinical Medical College of Jinan University, Shenzhen 518020, China; School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.
  • 2. Department of Infectious Disease, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology and The Second Clinical Medical College of Jinan University, Shenzhen 518020, China.
  • 3. Department of Infectious Disease, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology and The Second Clinical Medical College of Jinan University, Shenzhen 518020, China; School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China. Electronic address: [email protected].
  • 4. Department of Infectious Disease, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology and The Second Clinical Medical College of Jinan University, Shenzhen 518020, China; School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China. Electronic address: [email protected].
PMID: 37741706 DOI: 10.1016/j.tibtech.2023.08.005
Abstract

Genetically engineered immune cells expressing chimeric antigen receptors (CARs) have emerged as a new game changer in Cancer Immunotherapy. The utility of CAR T cell therapy against hematological malignancies has been validated in clinical practice. Other CAR immune cells are currently under investigation to improve the potency of CAR therapy in solid tumors. As a new class of therapeutic modalities, mRNA-based therapeutics hold enormous potential beyond COVID-19 mRNA vaccines. Arming immune cells with mRNA-encoded CARs represents a new frontier in Cancer and beyond, enabling in vivo generation of CAR cells without causing transgene integration. In this review, we summarize recent advances in mRNA-based CAR immunotherapies and highlight their opportunities and challenges for the development of a new generation of living drugs.

Keywords
chimeric antigen receptor; delivery system; immune cell; immunotherapy; mRNA.
Products